Where frailty meets diabetes

Diabetes/Metabolism Research and Reviews

Volumn 32, Issue , 2016, Pages 261-267

  Perkisas, Stany ^a   Vandewoude, Maurits ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Diabetes; Elderly; Frailty; Sarcopenia; Ulcer

Indexed keywords

GLUCOSE; IMMUNOLOGIC FACTOR; INSULIN;

AGING; ARTICLE; DIABETES MELLITUS; DISEASE ASSOCIATION; FOOT ULCER; FRAILTY; GLUCONEOGENESIS; GLUCOSE TRANSPORT; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; MUSCLE MASS; NONHUMAN; PATHOPHYSIOLOGY; PHYSICAL DISEASE BY BODY FUNCTION; PRIORITY JOURNAL; SARCOPENIA; AGED; COGNITIVE AGING; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC FOOT; DISEASE COURSE; EVIDENCE BASED MEDICINE; FRAIL ELDERLY; LIFESTYLE; MULTIMODALITY CANCER THERAPY; ORGANIZATION; PERSONALIZED MEDICINE; SEVERITY OF ILLNESS INDEX; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COGNITIVE AGING; COMBINED MODALITY THERAPY; CONGRESSES AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC FOOT; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; FRAIL ELDERLY; HUMANS; LIFE STYLE; PRECISION MEDICINE; SARCOPENIA; SEVERITY OF ILLNESS INDEX;

EID: 84956739790     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2743     Document Type: Article

References (90)

1. Morley JE. Diabetes and aging: epidemiologic overview. Clin Geriatr Med 2008; 24(3): 395-405 v.
2. Wong E, Backholer K, Gearon E, et al. Diabetes and risk of physical disability in adults: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2013; 1(2): 106-14.
3. Mazza AD, Morley JE. Update on diabetes in the elderly and the application of current therapeutics. J Am Med Dir Assoc 2007; 8(8): 489-92.
4. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 2004; 59(3): 255-63.
5. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286(3): 327-34.
6. van Exel E, Gussekloo J, deCraen AJ, et al. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes 2002; 51(4): 1088-92.
7. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27(3): 813-23.
8. McInnes IB, Gracie JA. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004; 4(4): 392-7.
9. Wen Y, Gu J, Li SL, Reddy MA, Natarajan R, Nadler JL. Elevated glucose and diabetes promote interleukin-12 cytokine gene expression in mouse macrophages. Endocrinology 2006; 147(5): 2518-25.
10. Donath MY, Storling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J Mol Med (Berl) 2003; 81(8): 455-70.
11. Hartman ME, O'Connor JC, Godbout JP, Minor KD, Mazzocco VR, Freund GG. Insulin receptor substrate-2-dependent interleukin-4 signaling in macrophages is impaired in two models of type 2 diabetes mellitus. J Biol Chem 2004; 279(27): 28045-50.
12. Spranger J, Kroke A, Mohlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52(3): 812-7.
13. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356(15): 1517-26.
14. De Martinis M, Franceschi C, Monti D, Ginaldi L. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett 2005; 579(10): 2035-2039.
15. Cannizzo ES, Clement CC, Sahu R, Follo C, Santambrogio L. Oxidative stress, inflamm-aging and immunosenescence. J Proteomics 2011; 74(11): 2313-23.
16. Heffner KL. Neuroendocrine effects of stress on immunity in the elderly: implications for inflammatory disease. Immunol Allergy Clin North Am 2011; 31(1): 95-108.
17. Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage 2013; 21(1): 16-21.
18. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci 2014; 69(Suppl 1): S4-9.
19. Varadhan R, Yao W, Matteini A, et al. Simple biologically informed inflammatory index of two serum cytokines predicts 10 year all-cause mortality in older adults. J Gerontol A Biol Sci Med Sci 2014; 69(2): 165-73.
20. Cesari M, Penninx BW, Pahor M, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci 2004; 59(3): 242-8.
21. Sinclair AJ. Diabetes in the elderly: a perspective from the United Kingdom. Clin Geriatr Med 1999; 15(2): 225-37.
22. Woods NF, LaCroix AZ, Gray SL, et al. Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study. J Am Geriatr Soc 2005; 53(8): 1321-30.
23. Rockwood K, Mitnitski A. Frailty defined by deficit accumulation and geriatric medicine defined by frailty. Clin Geriatr Med 2011; 27(1): 17-26.
24. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56(3): M146-56.
25. Thabit H, Kyaw Tun T, McDermott J, Sreenan S. Executive function and diabetes mellitus-a stone left unturned? Curr Diabetes Rev 2012; 8(2): 109-15.
26. Saum KU, Dieffenbach AK, Muller H, Holleczek B, Hauer K, Brenner H. Frailty prevalence and 10-year survival in community-dwelling older adults: results from the ESTHER cohort study. Eur J Epidemiol 2014; 29(3): 171-9.
27. Jung HW, Kim SW, Ahn S, et al. Prevalence and outcomes of frailty in Korean elderly population: comparisons of a multidimensional frailty index with two phenotype models. PLoS One 2014; 9(2): e87958.
28. Morley JE. Frailty: diagnosis and management. J Nutr Health Aging 2011; 15(8): 667-70.
29. Lee JS, Auyeung TW, Leung J, Kwok T, Leung PC, Woo J. Physical frailty in older adults is associated with metabolic and atherosclerotic risk factors and cognitive impairment independent of muscle mass. J Nutr Health Aging 2011; 15(10): 857-62.
30. Ottenbacher KJ, Graham JE, Al Snih S, et al. Mexican Americans and frailty: findings from the Hispanic established populations epidemiologic studies of the elderly. Am J Public Health 2009; 99(4): 673-9.
31. Hubbard RE, Andrew MK, Fallah N, Rockwood K. Comparison of the prognostic importance of diagnosed diabetes, co-morbidity and frailty in older people. Diabet Med 2010; 27(5): 603-6.
32. Cacciatore F, Testa G, Galizia G, et al. Clinical frailty and long-term mortality in elderly subjects with diabetes. Acta Diabetol 2013; 50(2): 251-60.
33. Bouillon K, Kivimaki M, Hamer M, et al. Diabetes risk factors, diabetes risk algorithms, and the prediction of future frailty: the Whitehall II prospective cohort study. J Am Med Dir Assoc 2013; 14(11851 e1-6).
34. Tang Z, Wang C, Song X, et al. Co-occurrence of cardiometabolic diseases and frailty in older Chinese adults in the Beijing Longitudinal Study of Ageing. Age Ageing 2013; 42(3): 346-51.
35. Lee JS, Auyeung TW, Leung J, Kwok T, Woo J. Transitions in frailty states among community-living older adults and their associated factors. J Am Med Dir Assoc 2014; 15(4): 281-6.
36. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39(4): 412-23.
37. Sehl ME, Yates FE. Kinetics of human aging: I. Rates of senescence between ages 30 and 70 years in healthy people. J Gerontol A Biol Sci Med Sci 2001; 56(5): B198-208.
38. Vandervoort AA. Aging of the human neuromuscular system. Muscle Nerve 2002; 25(1): 17-25.
39. Morley JE, Malmstrom TK, Rodriguez-Manas L, Sinclair AJ. Frailty, sarcopenia and diabetes. J Am Med Dir Assoc 2014; 15(12): 853-9.
40. Roubenoff R, Hughes VA. Sarcopenia: current concepts. J Gerontol A Biol Sci Med Sci 2000; 55(12): M716-24.
41. Lee CG, Boyko EJ, Strotmeyer ES, et al. Association between insulin resistance and lean mass loss and fat mass gain in older men without diabetes mellitus. J Am Geriatr Soc 2011; 59(7): 1217-24.
42. Rasmussen BB, Fujita S, Wolfe RR, et al. Insulin resistance of muscle protein metabolism in aging. FASEB J 2006; 20(6): 768-9.
43. Lee CG, Boyko EJ, Barrett-Connor E, et al. Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes Care 2011; 34(11): 2381-6.
44. Lee CG, Boyko EJ, Nielson CM, et al. Mortality risk in older men associated with changes in weight, lean mass, and fat mass. J Am Geriatr Soc 2011; 59(2): 233-40.
45. Casellini CM, Vinik AI. Clinical manifestations and current treatment options for diabetic neuropathies. Endocr Pract 2007; 13(5): 550-66.
46. Fahim MA, Hasan MY, Alshuaib WB. Early morphological remodeling of neuromuscular junction in a murine model of diabetes. J Appl Physiol (1985) 2000; 89(6): 2235-40.
47. Wang F, Liao Y, Li X, Ren C, Cheng C, Ren Y. Increased circulating myostatin in patients with type 2 diabetes mellitus. J Huazhong Univ Sci Technolog Med Sci 2012; 32(4): 534-9.
48. Abbatecola AM, Ferrucci L, Ceda G, et al. Insulin resistance and muscle strength in older persons. J Gerontol A Biol Sci Med Sci 2005; 60(10): 1278-82.
49. Wolfe RR. The underappreciated role of muscle in health and disease. Am J Clin Nutr 2006; 84(3): 475-82.
50. Perkisas S, Chong YM, Vandewoude M. Intramuscular adipose tissue and the functional components of sarcopenia. EUR GERIATR MED 2014; 5(suppl. 1): S79.
51. Goodpaster BH, Chomentowski P, Ward BK, et al. Effects of physical activity on strength and skeletal muscle fat infiltration in older adults: a randomized controlled trial. J Appl Physiol (1985) 2008; 105(5): 1498-503.
52. Delmonico MJ, Harris TB, Visser M, et al. Longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am J Clin Nutr 2009; 90(6): 1579-85.
53. Perkisas S, Chong YM, Vandewoude M. Intramuscular adipose tissue and survival in geriatric inpatients. EUR GERIATR MED 2014; 5(suppl. 1): S198-S199.
54. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1(7285): 785-9.
55. Sial S, Coggan AR, Carroll R, Goodwin J, Klein S. Fat and carbohydrate metabolism during exercise in elderly and young subjects. Am J Physiol 1996; 271(6 Pt 1): E983-9.
56. Kelley DE, Goodpaster B, Wing RR, Simoneau JA. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol 1999; 277(6 Pt 1): E1130-41.
57. Wang X, Hu Z, Hu J, Du J, Mitch WE. Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology 2006; 147(9): 4160-8.
58. Sriram S, Subramanian S, Juvvuna PK, et al. Myostatin induces DNA damage in skeletal muscle of streptozotocin-induced type 1 diabetic mice. J Biol Chem 2014; 289(9): 5784-98.
59. Fujita S, Rasmussen BB, Cadenas JG, Grady JJ, Volpi E. Effect of insulin on human skeletal muscle protein synthesis is modulated by insulin-induced changes in muscle blood flow and amino acid availability. Am J Physiol Endocrinol Metab 2006; 291(4): E745-54.
60. Abbatecola AM, Paolisso G, Fattoretti P, et al. Discovering pathways of sarcopenia in older adults: a role for insulin resistance on mitochondria dysfunction. J Nutr Health Aging 2011; 15(10): 890-5.
61. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15(3): 318-68.
62. Park SW, Goodpaster BH, Strotmeyer ES, et al. Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes 2006; 55(6): 1813-8.
63. Kim KS, Park KS, Kim MJ, Kim SK, Cho YW, Park SW. Type 2 diabetes is associated with low muscle mass in older adults. Geriatr Gerontol Int 2014; 14(Suppl 1): 115-21.
64. Anbalagan VP, Venkataraman V, Pradeepa R, Deepa M, Anjana RM, Mohan V. The prevalence of presarcopenia in Asian Indian individuals with and without type 2 diabetes. Diabetes Technol Ther 2013; 15(9): 768-75.
65. Park SW, Goodpaster BH, Strotmeyer ES, et al. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes Care 2007; 30(6): 1507-12.
66. Park SW, Goodpaster BH, Lee JS, et al. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care 2009; 32(11): 1993-7.
67. Prior SJ, Goldberg AP, Ortmeyer HK, et al. Increased skeletal muscle capillarization independently enhances insulin sensitivity in older adults after exercise training and detraining. Diabetes 2015.
68. Morley JE. Androgens and aging. Maturitas 2001; 38(1): 61-71 discussion 71-3.
69. Rockwood K, Tan M, Phillips S, McDowell I. Prevalence of diabetes mellitus in elderly people in Canada: report from the Canadian Study of Health and Aging. Age Ageing 1998; 27(5): 573-7.
70. Sinha-Hikim I, Cornford M, Gaytan H, Lee ML, Bhasin S. Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older men. J Clin Endocrinol Metab 2006; 91(8): 3024-33.
71. Banerjee M, Saxena M. Interleukin-1 (IL-1) family of cytokines: role in type 2 diabetes. Clin Chim Acta 2012; 413(15-16): 1163-70.
72. Steensberg A, Febbraio MA, Osada T, et al. Interleukin-6 production in contracting human skeletal muscle is influenced by pre-exercise muscle glycogen content. J Physiol 2001; 537(Pt 2): 633-9.
73. King DS, Dalsky GP, Clutter WE, et al. Effects of exercise and lack of exercise on insulin sensitivity and responsiveness. J Appl Physiol (1985) 1988; 64(5): 1942-6.
74. Michaud M, Balardy L, Moulis G, et al. Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc 2013; 14(12): 877-82.
75. Bales CW, Ritchie CS. Sarcopenia, weight loss, and nutritional frailty in the elderly. Annu Rev Nutr 2002; 22: 309-23.
76. von Haehling S, Morley JE, Anker SD. From muscle wasting to sarcopenia and myopenia: update 2012. J Cachexia Sarcopenia Muscle 2012; 3(4): 213-7.
77. Wedick NM, Barrett-Connor E, Knoke JD, Wingard DL. The relationship between weight loss and all-cause mortality in older men and women with and without diabetes mellitus: the Rancho Bernardo study. J Am Geriatr Soc 2002; 50(11): 1810-5.
78. MacIntosh C, Morley JE, Chapman IM. The anorexia of aging. Nutrition 2000; 16(10): 983-95.
79. Khan MS, Chandanpreet S, Kewal K, Sanjay D, Ram KJ, Atul S. Malnutrition, anthropometric, and biochemical abnormalities in patients with diabetic nephropathy. J Ren Nutr 2009; 19(4): 275-82.
80. Morley JE, Silver AJ. Anorexia in the elderly. Neurobiol Aging 1988; 9(1): 9-16.
81. Andersen H, Nielsen S, Mogensen CE, Jakobsen J. Muscle strength in type 2 diabetes. Diabetes 2004; 53(6): 1543-8.
82. Nomura T, Ikeda Y, Nakao S, et al. Muscle strength is a marker of insulin resistance in patients with type 2 diabetes: a pilot study. Endocr J 2007; 54(5): 791-6.
83. Leenders M, Verdijk LB, van derHoeven L, et al. Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. J Am Med Dir Assoc 2013; 14(8): 585-92.
84. Volpato S, Bianchi L, Lauretani F, et al. Role of muscle mass and muscle quality in the association between diabetes and gait speed. Diabetes Care 2012; 35(8): 1672-9.
85. Kalyani RR, Tra Y, Yeh HC, Egan JM, Ferrucci L, Brancati FL. Quadriceps strength, quadriceps power, and gait speed in older U.S. adults with diabetes mellitus: results from the National Health and Nutrition Examination Survey, 1999-2002. J Am Geriatr Soc 2013; 61(5): 769-75.
86. Whitmer RA. Type 2 diabetes and risk of cognitive impairment and dementia. Curr Neurol Neurosci Rep 2007; 7(5): 373-80.
87. Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes-systematic overview of prospective observational studies. Diabetologia 2005; 48(12): 2460-9.
88. Hsiung GY, Sadovnick AD, Feldman H. Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. CMAJ 2004; 171(8): 863-7.
89. Accardi G, Caruso C, Colonna-Romano G, Camarda C, Monastero R, Candore G. Can Alzheimer disease be a form of type 3 diabetes? Rejuvenation Res 2012; 15(2): 217-21.
90. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA 2005; 293(2): 217-28.